+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Optimal indications for second-line chemotherapy in advanced gastric cancer



Optimal indications for second-line chemotherapy in advanced gastric cancer



Anti-Cancer Drugs 23(4): 465-470



As it remains uncertain whether patients with advanced gastric cancer who progress after first-line chemotherapy should receive second-line chemotherapy, we attempted to identify the optimal indications for second-line chemotherapy. In this retrospective study, 101 patients were included in univariate and multivariate analyses to identify clinicopathological variables independently associated with longer survival postprogression (SPP), defined as the time from recognition of disease progression on first-line chemotherapy to death from any cause or last follow-up. The median SPP was 340 days. On multivariate analysis, performance status 2 [hazard ratio (HR), 14.234; 95% confidence interval (CI), 2.766-73.258], serum albumin level less than 3.5 g/dl (HR, 2.088; 95% CI, 1.047-4.060) at initiation of second-line chemotherapy, and time to progression less than 170 days on first-line chemotherapy (HR, 2.497; 95% CI, 1.227-5.083) were identified as independent prognostic factors associated with shorter SPP. The median SPP was 496, 375, and 232 days in patients with 0, 1, and 2 of these 3 negative prognostic factors, respectively (P=0.0002). The present study suggests that second-line chemotherapy would not be beneficial in patients with two or more of the following three negative prognostic factors: performance status 2, serum albumin less than 3.5 g/dl at initiation of second-line chemotherapy and time to progression less than 170 days on first-line chemotherapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 054769165

Download citation: RISBibTeXText

PMID: 22227714

DOI: 10.1097/CAD.0b013e3283504442


Related references

Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. Journal of Cancer Research and Clinical Oncology 136(7): 1059-1064, 2010

Optimal chemotherapy for advanced gastric cancer: is there a global consensus?. Gastric Cancer 17(2): 213-225, 2014

Chemotherapy beyond second-line in advanced gastric cancer. World Journal of Gastroenterology 21(29): 8811-8816, 2016

Optimal indications of surgical palliation for incurable advanced gastric cancer presenting with malignant gastrointestinal obstruction. Gastric Cancer 14(4): 353-359, 2012

Second-line chemotherapy for advanced gastric cancer in Korea. Gastric Cancer 15(4): 345-354, 2013

Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet. Oncology 10(9): 903-912, 2009

Second-line chemotherapy with mitomycin C and S-1 in patients with advanced gastric cancer. Journal of Clinical Oncology 24(18_suppl): 14083-14083, 2016

Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy. Onkologie 28(10): 499-502, 2005

Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Annals of Oncology 24(11): 2850-2854, 2014

Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer. Medical Oncology 27(3): 992-997, 2010

Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. European Journal of Cancer 49(14): 3003-3009, 2013

Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer. Korean Journal of Gastroenterology 66(1): 1-4, 2016

Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer. Expert Review of Anticancer Therapy 14(8): 887-900, 2015

Clinical experience of second-line chemotherapy with S-1/CPT-11 for highly advanced gastric cancer. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 35(2): 245-250, 2008